The Trump administration has moved forward with targeted tariffs on pharmaceutical manufacturers, marking a significant escalation in federal efforts to address drug pricing and domestic production.  

Under the policy, companies that have not entered into pricing and manufacturing agreements with the administration could face tariffs of up to 100%, enabled through a Section 232 national security designation. Meanwhile, several large manufacturers, including Pfizer and Eli Lilly, have secured temporary exemptions by aligning with federal expectations around U.S. investment and pricing tied to the administration’s broader TrumpRx framework.  

The policy establishes a tiered structure. Companies that agree to most-favored-nation (MFN) pricing and commit to U.S.-based manufacturing may reduce tariffs significantly, in some cases to zero, while those that do not could face the full 100% rate. Companies can reduce tariffs to approximately 20% during the buildout of U.S. manufacturing facilities, with full relief contingent on completing domestic production commitments by 2029.  

Generic and biosimilar manufacturers are largely exempt, further concentrating the impact on patented, branded therapies.  

The U.S. accounts for roughly 40–45% of global pharmaceutical revenue, underscoring why pricing and manufacturing policy shifts here have global implications.  

This is more than a trade action. It reflects a broader shift in how policymakers are approaching pharmaceutical economics, linking pricing, supply chain resilience, and national security into a more unified policy strategy.  

Who Feels This First?  

Pharmaceutical manufacturers face immediate strategic pressure  

Tariffs introduce new financial and operational considerations for companies that have not aligned with emerging pricing and domestic manufacturing expectations. This accelerates decision-making timelines around pricing concessions, U.S. investment, and portfolio prioritization.  

Patented and branded drugs represent the majority of U.S. drug spending, meaning targeted tariffs in this segment can have outsized financial impact.  

Mid-sized and emerging biotech companies may face disproportionate exposure  

Unlike large, diversified manufacturers, many mid-sized biotechs rely on a small number of patented therapies and lack the scale to absorb tariff-related cost increases or quickly shift manufacturing.  

Industry groups have raised concerns that the structure creates a two-tiered system, where larger companies with existing agreements or manufacturing capacity are insulated, while smaller innovators face greater financial risk.  

Payers and PBMs face contracting complexity  

If pricing varies based on policy alignment, formulary decisions and rebate structures may need to evolve. Cost assumptions built into current contracts could require reassessment, particularly in Medicare and commercial lines of business.  

U.S. prescription drug spending has exceeded $600 billion annually, amplifying the system-wide implications of even targeted pricing changes.  

Providers face operational variability  

Health systems and hospitals may see shifts in drug availability, sourcing, or acquisition costs, particularly for branded and specialty therapies.  

Short-term variability may emerge as manufacturers adjust supply chains or pricing strategies in response to tariff timelines and exemption criteria.  

Patients ultimately feel the downstream effects  

Whether through formulary changes, cost-sharing adjustments, or access limitations, patients are likely to experience the consequences of these policy shifts as changes move through the system.  

The Communications Challenge: Competing Narratives & Uncertainty  

This policy introduces a set of overlapping, and at times, competing narratives:  

  • Affordability: Efforts to lower drug prices through TrumpRx and related policies   
  • Innovation: The need to sustain long-term R&D investment   
  • Access: Concerns around supply continuity and coverage decisions   
  • Supply chain resilience: Domestic manufacturing as a national security priority   

Organizations will need to navigate these perspectives carefully, particularly as different stakeholders experience the policy unevenly.  

Strategic Communications Imperatives  

Lead with patient impact and prioritization, not policy mechanics  

Audiences are less focused on trade authority or pricing frameworks and more on practical outcomes. The key question remains: how will this affect affordability and access?  

Acknowledge operational realities with clarity  

For pharmaceutical companies, pricing and manufacturing decisions are complex and interdependent. Messaging that reflects these dynamics while reinforcing commitments to innovation and patient access will carry more credibility.  

Prepare for uneven impact narratives  

Given the tiered structure, stakeholders will quickly recognize that not all companies or therapies are affected equally. Communications should anticipate questions around fairness, competition, and differential impact across the industry.  

Prepare for shifting cost narratives  

Payers and providers may face increased scrutiny around whether policy-driven changes translate into lower out-of-pocket costs. Clear articulation of how savings or pressures move through the system will be important.  

Align policy, investor, and public messaging  

Companies will be communicating simultaneously to regulators, investors, providers, and patients. Consistent but strategically nuanced messaging across these audiences will be critical to maintaining credibility.  

Emphasize stability and continuity of care  

Providers and supply chain stakeholders should proactively reinforce stability in drug availability and patient care, particularly if sourcing or formulary decisions evolve.  

MWW Health Recommendations   

Pressure-test your patient impact narrative  

Be prepared to answer a simple question: will this policy make medications more affordable or harder to access? Align internal stakeholders on a clear, fact-based position.  

Align policy, investor, and communications teams  

Tariffs tied to pricing and domestic manufacturing will generate attention across multiple audiences. Consistent messaging is critical to maintaining credibility.  

Audit exposure to pricing and supply changes  

Identify where tariff-driven shifts could affect pricing, sourcing, or formulary decisions. Communications should reflect operational realities, not assumptions.  

Prepare reactive messaging now  

Develop holding statements addressing potential cost impacts, continuity of care, manufacturing or sourcing changes, and commitment to innovation and access.  

Monitor stakeholder sentiment closely  

Track how patient groups, provider associations, industry organizations, and policymakers frame the issue. Early narratives around affordability, innovation, and fairness will shape the broader conversation.  

Decide your proactive posture  

Organizations should determine whether to emphasize affordability and domestic manufacturing goals, highlight innovation and investment considerations, focus on patient access and system stability, or maintain a balanced position.  

Bottom Line  

Pharmaceutical manufacturers may experience the most immediate impact, but the broader conversation will center on patients, access, and stability for a system that is already managing significant, multifaceted transformation.  

At the same time, the policy’s tiered structure introduces new questions around competitive balance, particularly for mid-sized biotech companies and emerging innovators.  

As pricing, manufacturing, and policy priorities continue to converge, stakeholders across the healthcare system will be asked a common question: who benefits, and how are impacts distributed?  

Organizations that communicate clearly, acknowledge complexity, and stay grounded in real-world impact will be best positioned as this policy evolves. Those that remain silent and refuse to develop contingency plans do so at their own risk.